Thorsten Fischer

Thorsten Fischer

Auto-generated profile, based on publicly available information

Thorsten Fischer

Universitätsklinik für Geburtshilfe und Gynäkologie, Paracelsus Medical University, Salzburg, Österreich

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 November 1996 in New England Journal of Medicine
Verified
Journal Article
Open access
PDF file
HSHans P. Schobel
Hans P. Schobel
TFThorsten Fischer
Thorsten Fischer
KHKarsten Heuszer
Karsten Heuszer
HGHelmut Geiger
Helmut Geiger
RSRoland E. Schmieder
Roland E. Schmieder
Preeclampsia is characterized by a marked increase in peripheral vascular resistance leading to an increase in blood pressure, but the triggering mechanisms are unclear. To determine whether augmented sympathetic vasoconstrictor activity may be an important mechanism in mediating the increase in vasomotor tone, we measured postganglionic sympathetic-nerve activity in the blood vessels of skeletal muscle by means of intraneural microelectrodes in nine women with preeclampsia, eight normotensive pregnant women, six normotensive nonpregnant women, and seven nonpregnant women with hypertension, both at rest and during noninvasive cardiovascular-reflex testing (with the Valsalva maneuver and the cold pressor test). The mean (±SE) rate of sympathetic-nerve activity in the normotensive pregnant women (10±1 bursts per minute) was not significantly different from that in normotensive nonpregnant women (12±2 bursts per minute) or hypertensive nonpregnant women (15±3 bursts per minute). In contrast, the rate of sympathetic-nerve activity in the patients with preeclampsia (33±3 bursts per minute) was more than three times as high as that in the normotensive pregnant women (P<0.05) and more than twice as high as in the group of nonpregnant women with hypertension (P<0.05). Hemodynamic and sympathetic-nerve responses to both reflex tests did not differ significantly among the four groups. Six patients with preeclampsia were studied again after delivery; mean sympathetic-nerve activity at that time had decreased significantly from the value during pregnancy (from 36±4 to 13±2 bursts per minute, P<0.01), as had mean arterial pressure (from 118±3 to 96±1 mm Hg, P<0.01). Preeclampsia is a state of sympathetic overactivity, which reverts to normal after delivery. Our data indicate that the increases in peripheral vascular resistance and blood pressure that characterize this disorder are mediated, at least in part, by a substantial increase in sympathetic vasoconstrictor activity.

16 June 2004 in European Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
TFT. Fischer
T. Fischer
HSH. P. Schobel
H. P. Schobel
HFH. Frank
H. Frank
MAM. Andreae
M. Andreae
KSK. T. M. Schneider
K. T. M. Schneider
KHK. Heusser
K. Heusser

6 October 2005 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
TFThorsten Fischer
Thorsten Fischer
HNHans‐Hellmut Neumayer
Hans‐Hellmut Neumayer
RFRonald Fischer
Ronald Fischer
MBMichael Barenbrock
Michael Barenbrock
HSHans P. Schobel
Hans P. Schobel
KBKlemens Budde
Klemens Budde
In order to investigate the effect of different immunosuppressive regimens and the time interval between transplantation and pregnancy on long-term outcome, we performed a case-control study in pregnant renal allograft recipients. Eighty-one pregnancies of kidney transplanted recipients were identified [cyclosporine (CYA): n = 40; azathioprine (AZA): n = 41]. Controls were matched with respect to important prognostic factors. Posttransplant follow-up was 91.3 ± 5 months. Graft and patient survival were similar in both groups and there was no apparent effect of immunosuppression. A total of 28 recipients (33%) delivered within 2 years and 6 (8%) subjects within 1 year after transplantation, but these short transplantation-to-pregnancy intervals had no apparent adverse effect on long-term outcome. In contrast to AZA-treated patients, CYA-treated patients experienced an increase in serum creatinine postpartum (1.15 ± 0.2 mg/dL vs. 1.61 ± 0.1 mg/dL; p < 0.05). Whole blood CYA levels decreased transiently during pregnancy from 115.9 ± 8 ng/mL to 80.7 ± 7 ng/mL leading to a gradual increase in drug dose from 240 ± 14 mg/day to 324 ± 21 mg/day (p < 0.05). Following delivery, there was an increase in CYA concentrations to 173 ± 5.4 ng/mL, requiring rapid dose tapering to baseline of 246 ± 15 mg/day. Pregnancies in renal recipients do not affect long-term patient and graft survival, independent of the immunosuppression. No detrimental effect of short transplantation-to-pregnancy intervals on long-term graft function was detected.

26 March 2004 in Ultrasound in Obstetrics & Gynecology
Verified
Journal Article
Closed access
PDF file
JOJ. U. Ortiz
J. U. Ortiz
EOE. Ostermayer
E. Ostermayer
TFT. Fischer
T. Fischer
BKB. Kuschel
B. Kuschel
MRM. Rudelius
M. Rudelius
KSK. T. M. Schneider
K. T. M. Schneider

1 September 2003 in Clinical Science
Verified
Journal Article
Closed access
Dietmar SchlembachDietmar Schlembach
Dietmar Schlembach
EBErnst Beinder
Ernst Beinder
JZJuergen Zingsem
Juergen Zingsem
UWUte Wunsiedler
Ute Wunsiedler
MBMatthias W. Beckmann
Matthias W. Beckmann
TFThorsten Fischer
Thorsten Fischer
This study was conducted to investigate the association of maternal and/or fetal factor V Leiden (FVL) and G20210A prothrombin mutation with HELLP syndrome. FVL and G20210A prothrombin mutation were determined using PCR. Sixty-three pregnant women, 36 of them diagnosed with HELLP syndrome, were included in the study. Overall, 68 children were born as a result of these pregnancies and blood sampling was possible in 28 out of 39 children from HELLP patients and 25 out of 29 children from the control women. The prevalence of a maternal FVL was elevated 2-fold in HELLP patients compared with the control women [six out of 36 (16.7%) compared with two out of 27 (7.4%); P=0.282]. None of the HELLP patients and only one woman in the control group was found to be positive for the G20210A prothrombin mutation (P=0.251). The fetal carrier frequency was four out of 28 compared with three out of 25 for FVL (P=0.811), and two out of 28 compared with one out of 25 for G20210A prothrombin mutation (P=0.629). Intrauterine growth restriction (IUGR) was significantly higher in fetuses found to be positive for a thrombophilic mutation (P=0.022). IUGR occurred in seven out of ten fetuses with a thrombophilic mutation compared with 11 out of 43 in fetuses without a mutation. The prevalence of FVL, but not of the G20210A prothrombin mutation, seems to be elevated in women with HELLP syndrome. A fetal thrombophilic mutation does not contribute significantly to the clinical features of the HELLP syndrome. Our results demonstrate a fetal contribution to IUGR. Fetal thrombophilic mutations may lead to placental microthrombosis, which consecutively could lead to a disturbed fetoplacental blood flow and thus cause growth restriction.

12 October 2016 in BMJ Open
Verified
Journal Article
Open access
PDF file
EHE. A. Huhn
E. A. Huhn
TFT Fischer
T Fischer
CGChristian Göbl
Christian Göbl
MBM Todesco Bernasconi
M Todesco Bernasconi
MKM Kreft
M Kreft
IHI Hoesli
I Hoesli
Introduction As the accurate diagnosis and treatment of gestational diabetes mellitus (GDM) is of increasing importance; new diagnostic approaches for the assessment of GDM in early pregnancy were recently suggested. We evaluate the diagnostic power of an ‘early’ oral glucose tolerance test (OGTT) 75 g and glycosylated fibronectin (glyFn) for GDM screening in a normal cohort. Methods and analysis In a prospective cohort study, 748 singleton pregnancies are recruited in 6 centres in Switzerland, Austria and Germany. Women are screened for pre-existing diabetes mellitus and GDM by an ‘early’ OGTT 75 g and/or the new biomarker, glyFn, at 12–15 weeks of gestation. Different screening strategies are compared to evaluate the impact on detection of GDM by an OGTT 75 g at 24–28 weeks of gestation as recommended by the International Association of Diabetes and Pregnancy Study Groups (IADPSG). A new screening algorithm is created by using multivariable risk estimation based on ‘early’ OGTT 75 g and/or glyFn results, incorporating maternal risk factors. Recruitment began in May 2014. Ethics and dissemination This study received ethical approval from the ethics committees in Basel, Zurich, Vienna, Salzburg and Freiburg. It was registered under http://www.ClinicalTrials.gov (NCT02035059) on 12 January 2014. Data will be presented at international conferences and published in peer-reviewed journals. Trial registration number NCT02035059.